aleksandar-sasa nikolic

* Key member of the top management team of one of the largest generics pharmaceutical companies, in charge of leading portfolio strategy development. * Developed strategies and associated business cases and plans for portfolio development * Made market strategic decisions in collaboration with business units’ directors (Hospital, Commercial, Rx, OTC) and supportive functions * Lead the Launch Management process by coordinating RA, Supply Chain, Marketing and other stakeholders to ensure timely launches * Managed local licensing/contract marketing management * Led flagship corporate initiatives, such as the conceptualization and execution of the Early Launch Opportunities project with more than 30 products in the pipeline – resulting in the first European launch of the generic Imatinib (2012) and Pregabalin (2014)

CEO of a start-up generic pharmaceutical company, responsible for business plan creation and execution, portfolio management, negotiations with suppliers, regulatory agencies, and other relevant parties, as well as day-to-day operational management of the company.

Team Lead/Consultant on consulting projects designed to aid the growing bio-pharmaceutical industry in the East of England region. - Managed projects such as: Grant Instruments Ltd (portfolio expansion), Regenerative Medicine Industry project (business model) - Conducted post-graduate research at the University of Cambridge focused on M&A and alliances in the pharmaceutical/biotech industries, and the impact of business and organizational model changes on product development and commercialization processes - Selected for a prestigious Engineering and Physical Sciences Research Council research funding award

Completed a Stamford Global course, led by Dr. Richard Bayney, former Merck&Co, Bayer Corp. and AG, BMS and J&J executive, focused on decision making under risk and uncertainty, advanced Portfolio Optimization and Prioritization frameworks, and risk and resource management. The course included training in the use of TreePlan, Crystall Ball, and Risk Solver Software Platforms.

Executive training course lead by Dr. Malcolm Ross, covering market models, strategy, latest development and opportunities for growth, M&As, IP and development issues in the industry.

The Master's in Bioscience Enterprise (MBE) programme is a multidisciplinary biotechnology and business degree course, designed for high-achieving individuals with an enthusiasm for enterprise. The course equips students with the requisite skills in enterprise, management and entrepreneurship required to take up executive roles, establish and build biotechnology companies or work in the life sciences consultancy sector.